Latest from Dexter Jie Yan
SinoCellTech's PD-1 inhibitor finotonlimab has become the first immuno-oncology drug to be approved in China for first-line head and neck squamous cell carcinoma regardless of PD-L1 expression.
Innogen is hoping the approval of its once-weekly GLP-1 drug Diabegone will allow it to chip away at Ozempic’s dominance in the Chinese diabetes market.
Plus deals involving Vanda/AnaptysBio, OS Therapies/Ayala, Leveragen/Moonlight Bio, Lantheus/Evergreen, Exicure/GPCR, Arrivent/Lepu, InnoCare/KeyMed/Prolium and more.
A combination of heightened competition, destocking at vaccination clinics and a slowing economy resulted in a disappointing year for major Chinese vaccine companies.
Degron and TargetRx’s targeted protein degrader programs helped the firms garner new venture capital backing, while VelaVigo and Conjustar were among the others bagging new funding for antibody- and peptide-drug conjugates.
Plus deals involving Simcere/AbbVie, Daiichi Sankyo/Glycotope, Telix/ImaginAb, Harbour/Kelun/Windward, Insilico/Menarini, Samsung Bioepis/Teva, HealZen/J&J, Zai Lab/Vertex, Zai Lab/MediLink and Primrose/Serum Institute of India.